DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

被引：2
|
作者：
Elgart, J. F. [1 ]
Prestes, M. [1 ]
Gonzalez, L. [1 ]
Aschner, P. [2 ]
Garrido Lecca, S. [3 ]
Aiello, E. [4 ]
Jimenez, C. [5 ]
Gagliardino, J. J. [1 ]
机构：
[1] UNLP CONICET La Plata, Ctr Colaborador OPS OMS, CENEXA Ctr Endocrinol Expt & Aplicada, Buenos Aires, DF, Argentina
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Bristol Myers Squibb Co, Lima, Peru
[4] Bristol Myers Squibb Co, Buenos Aires, DF, Argentina
[5] Bristol Myers Squibb Co, Bogota, Colombia
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1442
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A247 / A247
页数：1
相关论文
共 50 条
  • [1] DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COSTA RICA
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Vinocour, M.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [2] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    [J]. DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [3] The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Gordon, Jason
    McEwan, Phil
    Hurst, Michael
    Puelles, Jorge
    [J]. DIABETES THERAPY, 2016, 7 (04) : 825 - 845
  • [4] The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Jason Gordon
    Phil McEwan
    Michael Hurst
    Jorge Puelles
    [J]. Diabetes Therapy, 2016, 7 : 825 - 845
  • [5] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [6] DAPAGLIFLOZIN VERSUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA: COST-EFFECTIVENESS ANALYSIS
    Ordonez, J. E.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [7] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Nicholas Tentolouris
    Georgia Kourlaba
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2016, 36 : 649 - 659
  • [8] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659
  • [9] COST-EFFECTIVENESS ANALYSIS OF LINAGLIPTIN VERSUS SULFONYLUREA AS ADD-ON TREATMENT TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN INDONESIA
    Endarti, D.
    Kristin, E.
    Pratiwi, W. R.
    Pinzon, R. T.
    Nugrahaningsih, D. A.
    Yasmina, A.
    Febrinasari, R. P.
    [J]. VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [10] Triple therapy with saxagliptin and dapagliflozin add-on to metformin: safety of dual add-on versus sequential add-on
    Garcia-Sanchez, R.
    Del Prato, S.
    Matthaei, S.
    Iqbal, N.
    Hansen, L.
    Johnsson, E.
    Chen, H.
    Chin, A. J.
    Mathieu, C.
    [J]. DIABETOLOGIA, 2015, 58 : S356 - S356
12345